Twist Bioscience Corporation's stock plummeted 5.97% during intraday trading on Monday, following the release of its fiscal second-quarter 2026 financial results.

The significant drop came despite the company reporting quarterly sales of $110.7 million, which exceeded analyst estimates. Investors focused on the wider-than-anticipated net loss, which expanded to $44 million, or $0.71 per diluted share. This result missed the FactSet consensus estimate of a $0.50 loss per share. On an adjusted basis, the loss of $0.59 per share also fell short of the $(0.48) estimate.

While Twist Bioscience raised its full-year revenue outlook to a range of $442 million to $447 million, the substantial earnings miss appears to have driven negative sentiment, overshadowing the positive revenue guidance update.